<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624701</url>
  </required_header>
  <id_info>
    <org_study_id>2009/925/B</org_study_id>
    <nct_id>NCT01624701</nct_id>
  </id_info>
  <brief_title>Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells</brief_title>
  <official_title>Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells: A Pilot Trial in Collaboration With the Massachusetts Institute of Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Whitehead Institute for Biomedical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood Services Group, Health Sciences Authority of Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot clinical trial to assess the feasibility and efficacy of expanding umbilical&#xD;
      cord blood derived blood stem cells for transplantation using a combination of chemical&#xD;
      factors and stromal co-culture. Bone marrow (BM) mesenchymal stromal cells (MSC) will be&#xD;
      obtained from a separate bone marrow donor. One cord blood unit will be expanded by this&#xD;
      method while another cord blood unit will be infused without manipulation. The expanded cord&#xD;
      blood unit will help boost the initial recovery of blood counts after transplantation, though&#xD;
      it is expected that the unexpanded cord blood unit will provide the cells which will lead to&#xD;
      long term engraftment of blood stem cells. A third cord blood unit will be identified for&#xD;
      standby should the cord blood unit expansion fail.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Clinical transplantation of two cord blood units: one ex vivo expanded while another&#xD;
           unmanipulated unit to function as a back-up.&#xD;
&#xD;
        2. Ten patients will be selected from those for whom:&#xD;
&#xD;
             -  Allogeneic haematopoietic stem cell transplant is indicated (see details)&#xD;
&#xD;
             -  No matched sibling or matched unrelated donor is available quickly enough for the&#xD;
                transplant (no fully matched donor found within 1 month of initiation of donor&#xD;
                search or donor found but not available for donation within 3 months of donor&#xD;
                search).&#xD;
&#xD;
             -  At least three unrelated donor cord blood unit can be identified with less than 2&#xD;
                antigens mismatches with the patient but with insufficient cell dose to meet the&#xD;
                patient's requirements. If clinical efficacy of this protocol is demonstrated, we&#xD;
                will proceed to a multicentre clinical trial with more patients.&#xD;
&#xD;
        3. The investigators will obtain haplo-identical MSC from the bone marrow of&#xD;
           sibling/parent/offspring of the patient. Although there will be some MSC co-infused with&#xD;
           the cord blood cells, this has been shown to be safe in trials of MSC given for patients&#xD;
           with graft versus host disease (GVHD) and human leukocyte antigen (HLA) matching of MSC&#xD;
           and recipient has been shown to be not important. bone marrow mesenchymal stroma cells&#xD;
           (BM-MSCs) derived from related donor bone marrow with a minimum of 2/6 HLA match have&#xD;
           been safe for use in patients.1 If the haplo-identical MSC donor is not available,&#xD;
           matched unrelated donor MSC would also be used.&#xD;
&#xD;
        4. Efficacy will be assessed by the following and compared to published literature as well&#xD;
           as historical controls:&#xD;
&#xD;
             -  Neutrophil and platelet engraftment&#xD;
&#xD;
             -  Post transplant 100-day mortality&#xD;
&#xD;
             -  Overall and progression-free survival If clinical efficacy of this protocol is&#xD;
                demonstrated, the investigators will proceed to a multicentre clinical trial with&#xD;
                more patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding expired&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 month</time_frame>
    <description>Number of subjects with infusional toxicities (including fever, renal dysfunction within 72 hours of infusion) and potential immunologic competition (absent chimerism of donor cells by 21 days post transplantation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>2 months</time_frame>
    <description>Neutrophil engraftment (ANC&gt;500/ul) in subjects as demonstrated by number of subjects with engraftment &lt;=21 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Lymphoma</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Expanded</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>'Ex vivo expanded cord blood cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ex vivo expanded cord blood cells</intervention_name>
    <description>Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.</description>
    <arm_group_label>Expanded</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be from the Department of Haematology, Singapore General Hospital, who&#xD;
             have the diagnoses listed below and who meet the inclusion criteria. They have to be&#xD;
             deemed suitable for trial by the respective attending doctor as well as a panel of at&#xD;
             least three hematologists. Suitability will be reassessed by the Principal&#xD;
             Investigator again&#xD;
&#xD;
               1. Patients aged 12 years to 60 years.&#xD;
&#xD;
               2. Patient has no currently available HLA-A, B, C, DRB1 and DQB1 matched related or&#xD;
                  unrelated donor.&#xD;
&#xD;
               3. Patient must have a hematologic malignancy requiring allogeneic haematopoietic&#xD;
                  stem cell transplantation as further defined below (from National Marrow Donor&#xD;
                  Program and American Society of Blood and Marrow Transplantation Guidelines) and&#xD;
                  as further agreed upon by a panel of at least three hematologists specializing in&#xD;
                  transplantation.&#xD;
&#xD;
          -  Acute myelogenous leukemia (AML): High-risk AML including:&#xD;
&#xD;
               -  Antecedent hematological disease (e.g., myelodysplasia (MDS))&#xD;
&#xD;
               -  Treatment-related leukemia&#xD;
&#xD;
               -  Induction failure&#xD;
&#xD;
               -  1st complete remission (CR1) with poor-risk cytogenetics or molecular markers&#xD;
                  (e.g. Flt 3 mutation, 11q23 etc)&#xD;
&#xD;
               -  2nd complete remission (CR2) and beyond&#xD;
&#xD;
          -  Acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
               -  CR1 up to age 35&#xD;
&#xD;
               -  High-risk over age 35 including:&#xD;
&#xD;
               -  Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23&#xD;
                  rearrangements)&#xD;
&#xD;
               -  High white cell count (&gt; 30,000/mm3) at diagnosis&#xD;
&#xD;
               -  CNS or testicular leukemia&#xD;
&#xD;
               -  No CR within 4 weeks of initial treatment&#xD;
&#xD;
               -  Induction failure&#xD;
&#xD;
               -  CR2 and beyond&#xD;
&#xD;
          -  Myelodysplastic syndromes (MDS)&#xD;
&#xD;
               -  Intermediate-1 (INT-1), intermediate-2 (INT-2) or high IPSS score which includes:&#xD;
&#xD;
               -  &gt; 5% marrow blasts&#xD;
&#xD;
               -  Other than good risk cytogenetics (not 5q- or normal)&#xD;
&#xD;
               -  &gt; 1 lineage cytopenia&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
               -  Disease progression&#xD;
&#xD;
               -  Accelerated phase&#xD;
&#xD;
               -  Blast crisis (myeloid or lymphoid)&#xD;
&#xD;
          -  Follicular lymphoma&#xD;
&#xD;
               -  Poor response to initial treatment&#xD;
&#xD;
               -  After second or subsequent relapse&#xD;
&#xD;
               -  Transformation to diffuse large B-cell lymphoma&#xD;
&#xD;
          -  Aggressive T-cell or B-Cell lymphoma&#xD;
&#xD;
               -  After second or subsequent relapse&#xD;
&#xD;
               -  No CR with initial treatment&#xD;
&#xD;
          -  Mantle Cell: After second or subsequent relapse&#xD;
&#xD;
          -  Hodgkin's lymphoma&#xD;
&#xD;
               -  No initial CR&#xD;
&#xD;
               -  After second or subsequent relapse&#xD;
&#xD;
          -  Multiple myeloma: Patients failing autologous transplantation with chromosome 13&#xD;
             abnormalities, first response lasting less than 6 months, or Î²-2 microglobulin &gt; 3&#xD;
             mg/L may be considered for this protocol after initial therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inadequate Organ Function as defined by:&#xD;
&#xD;
               -  Renal: Creatinine clearance &gt; 60ml/min&#xD;
&#xD;
               -  Hepatic: Bilirubin, AST/ALT &lt; 2x upper limit of normal&#xD;
&#xD;
               -  Pulmonary function: DLCOcorr &gt; 50% normal&#xD;
&#xD;
               -  Cardiac: left ventricular ejection fraction &gt; 45%&#xD;
&#xD;
          2. Karnofsky score (adults) &lt; 70% or Lansky score &lt; 50% (pediatrics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William YK Hwang, MBBS, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>November 26, 2015</last_update_submitted>
  <last_update_submitted_qc>November 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord blood</keyword>
  <keyword>unrelated donor</keyword>
  <keyword>allogeneic</keyword>
  <keyword>cell dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

